http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110275027-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_db304b0b56a0b1201d8754af806cd838 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-12 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
| filingDate | 2019-07-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a45eff86ae9d5397fb66ebd7e51e0a7a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_74639e4359f440f156e057dae9df1ee0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_35b3b3614fbdf0fd25106868ab00f5d9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1d256d50919a44a5fc2a20498cad7fe6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_45985658a6ca84a1eaca0e90da2bd649 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e3f5b796523e04347f87bc4a28dc6450 |
| publicationDate | 2019-09-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-110275027-A |
| titleOfInvention | A biological marker used to assist in judging the pathological damage and/or prognosis of pulmonary tuberculosis |
| abstract | The present invention provides a biological marker for assisting in judging the pathological damage and/or prognosis of pulmonary tuberculosis, which is among TNF-α, IL-2, IFN-γ, MIG, TNF-β, GM-CSF, sAxl At least one of ; more preferably plasma sAxl. Application of the present invention Cytokine antibody chip technology was used to screen cytokines, and ELISA method was used to verify the plasma sAxl content. Then, the correlation analysis between plasma sAxl content and the severity of PTB pathological damage and prognosis was carried out. The results showed that plasma sAxl content not only It is closely related to PTB, and has a significant positive correlation with the severity of PTB pulmonary pathological damage and disease outcome, which indicates that plasma sAxl content can be a biomarker for predicting the severity of PTB pathological damage and disease outcome. |
| priorityDate | 2019-07-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 133.